Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression

TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ -- Approval based on a Phase 3 trial demonstrating Libtayo significantly improved overall survival compared to chemotherapy in advanced NSCLC that included challenging-to-treat patient populations Libtayo now approved by the European...

from PR Newswire: https://ift.tt/3d8D8uA